000154270 001__ 154270
000154270 005__ 20240229123059.0
000154270 0247_ $$2doi$$a10.1016/j.bbmt.2020.03.006
000154270 0247_ $$2pmid$$apmid:32194287
000154270 0247_ $$2ISSN$$a1083-8791
000154270 0247_ $$2ISSN$$a1523-6536
000154270 0247_ $$2altmetric$$aaltmetric:77982570
000154270 037__ $$aDKFZ-2020-00697
000154270 041__ $$aeng
000154270 082__ $$a610
000154270 1001_ $$aBlocka, Joanna$$b0
000154270 245__ $$aResponse improvement rather than response status after 1st ASCT is a significant prognostic factor for survival benefit from tandem compared to single ASCT in multiple myeloma patients.
000154270 260__ $$a[S.l.]$$bElsevier Health Sciences$$c2020
000154270 3367_ $$2DRIVER$$aarticle
000154270 3367_ $$2DataCite$$aOutput Types/Journal article
000154270 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1598860013_23423
000154270 3367_ $$2BibTeX$$aARTICLE
000154270 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154270 3367_ $$00$$2EndNote$$aJournal Article
000154270 500__ $$a2020 Jul;26(7):1280-1287
000154270 520__ $$aHigh-dose chemotherapy and autologous stem cell transplantation (ASCT) have been an effective treatment for newly diagnosed multiple myeloma patients for over three decades. However, it remains unclear which patients benefit from tandem compared to single ASCT. Here, we retrospectively analyzed 978 trial and non-trial patients who underwent single or tandem ASCT in Heidelberg or other German Speaking Myeloma Multicenter Group centers. Our results show that response improvement after 1st ASCT is a significant prognostic factor for progression-free survival benefit from tandem versus single ASCT (multivariable analysis p = 0.002, HR = 0.64, 95 % CI [0.48, 0.85], interaction p = 0.02). Depth of response after 1st ASCT and cytogenetic profile did not have a significant prognostic effect on survival benefit from tandem ASCT. In conclusion, our results suggest that not the response depth but rather response improvement after 1st ASCT is of prognostic significance regarding the benefit of tandem versus single ASCT.
000154270 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000154270 588__ $$aDataset connected to CrossRef, PubMed,
000154270 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$udkfz
000154270 7001_ $$aGoldschmidt, Hartmut$$b2
000154270 7001_ $$aDepartment of Hematology and Oncology, National Center for Tumor Diseases, Heidelberg, Germany.}$$b3
000154270 7001_ $$aHillengass, Jens$$b4
000154270 773__ $$0PERI:(DE-600)2057605-5$$a10.1016/j.bbmt.2020.03.006$$gp. S1083879120301439$$n7$$p1280-1287$$tBiology of blood and marrow transplantation$$v26$$x1083-8791$$y2020
000154270 909CO $$ooai:inrepo02.dkfz.de:154270$$pVDB
000154270 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000154270 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000154270 9141_ $$y2020
000154270 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000154270 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBIOL BLOOD MARROW TR : 2017
000154270 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000154270 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000154270 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000154270 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000154270 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000154270 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000154270 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000154270 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000154270 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000154270 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000154270 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000154270 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000154270 980__ $$ajournal
000154270 980__ $$aVDB
000154270 980__ $$aI:(DE-He78)C060-20160331
000154270 980__ $$aUNRESTRICTED